Loading...

Expanded CDMO And EU Investments Will Unlock Future Injectables Markets

Published
26 Dec 24
Updated
01 May 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-9.6%
7D
2.6%

Author's Valuation

€79.4125.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 01 May 25

Fair value Increased 2.95%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 1.10%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 3.21%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Increased 2.92%

AnalystConsensusTarget has decreased revenue growth from 9.6% to 8.5% and increased future PE multiple from 19.2x to 21.9x.

Shared on 19 Mar 25

Fair value Decreased 0.33%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Decreased 2.83%

AnalystConsensusTarget has increased revenue growth from 8.4% to 10.0% and decreased future PE multiple from 22.1x to 18.8x.